Canada announces funding, support for Can-ADAPT COVID platform led by U of T researcher

The Government of Canada has announced $10M in funding for the creation of a pan-Canadian platform to support research on COVID-19 treatments. The Canadian ADAptive Platform Trial of COVID-19 Therapeutics in Community Settings (Can-ADAPT COVID) is led by University of Toronto Professor Dr Andrew Pinto, and includes researchers from organizations such as NOSM University and the Research Institute of the McGill University Health Centre. Can-ADAPT COVID will focus on comparing the effects of oral COVID-19 medications with an aim of gaining an understanding of if the treatments prevent “long COVID.” Funding includes $5M from both the Canadian Institute of Health Research and Health Canada as well as relevant therapeutics from the Public Health Agency of Canada. NOSM| MUHC| Canada Note: Archived stories may contain dead links or be missing source links.

NOSM | Canada | Canada